Considering the role of MAEL in CSC regulation and the substantial effect of MAEL-targeting in impairing HCC tumor growth in mice, alone or in combination with sorafenib, it raises the possibility of the PTGS2 inhibitor as a combination treatment along with already available therapies for anti-cancer stemness-targeting in HCC [49,50]. Here, PTGS2 is linked to hepatocellular carcinoma.